Plant-based VLP experts in Strasbourg, France

Serendip today

The company was founded in 2023 in Strasbourg and builds on two decades of academic research in the underlying technology.

Its creation is a remarkable story of a successful meeting between two academic researchers—experts in plant biology and virology—and a pharmaceutical industry specialist with deep experience in managing product development and industrializing bioprocesses.

Team

Scientific

advisory board

PhD

François GHIRINGHELLI

Oncologist and clinical expert at CGFL

(Dijon, France)

Head of immunotherapy innovations and CLIP² clinical platform.
Expert in immunology, preclinical and clinical studies.

PhD

Jean-Pierre ABASTADO

Independent immuno-oncology consultant

Former R&D director at Servier, experienced expert in pharmaceutical industry, especially in designing preclinical and clinical studies.

PhD

Sébastien APCHER

Principal Investigator at Institute Gustave Roussy

(Villejuif, France)

Immuno-oncology expert in neoantigens discovery and validation.

PhD

Hélène DUMORTIER

Principal Investigator at IBMC

(Strasbourg, France)

Immunology expert, especially in Proof of Concepts.

PhD

Christophe RITZENHALER

Principal Investigator at IBMP

(Strasbourg, France)

Plant biology expert especially in engineering the VLP and optimizing the plant-based expression system.

Support

Facility

The team has access to a 440 m² facility equipped with R&D equipments for producing R&D batches of plants. A few dozen mg of VLP at the required quality is possible.

Batches for regulatory preclinical and clinical studies will be subcontracted to a CDMO specialized in plant-based manufacturing that has already been identified. A few dozen g to a few kg of VLP at the required quality is possible.

Finance

Serendip is currently seeking 3 million € in private investment to fund collaborative feasibility studies, as well as the pharmacology and toxicology studies necessary to de-risk safety aspects for our partners.

Over the next three years, Serendip will focus on demonstrating the versatility, efficacy, safety, and commercial potential of its platform.

If you’re interested in exploring investment opportunities, feel free to reach out via the contact form. Investments in deeptech innovation companies like Serendip may qualify for tax incentives, offering up to a 50% reduction on the invested amount.